A5104686581- Mitochondrial Function and Pathology
- ATP Synthase and ATPases Research
- Microtubule and mitosis dynamics
- Breast Cancer Treatment Studies
- DNA Repair Mechanisms
- Cancer Immunotherapy and Biomarkers
- Breast Implant and Reconstruction
- Cancer-related Molecular Pathways
- Advanced Radiotherapy Techniques
- AI in cancer detection
- RNA modifications and cancer
- Head and Neck Cancer Studies
- Breast Lesions and Carcinomas
- Retinoids in leukemia and cellular processes
- Ubiquitin and proteasome pathways
- Cancer, Hypoxia, and Metabolism
- RNA Research and Splicing
- Histiocytic Disorders and Treatments
- interferon and immune responses
- Nuclear Structure and Function
- Advanced Breast Cancer Therapies
- Single-cell and spatial transcriptomics
- Viral-associated cancers and disorders
- Cell death mechanisms and regulation
- Chemotherapy-induced cardiotoxicity and mitigation
Brigham and Women's Hospital
2024
Harvard University
2024
Yale University
2023-2024
SUNY Downstate Health Sciences University
2019-2021
Mayo Clinic
2016-2019
Mayo Clinic in Arizona
2016-2019
WinnMed
2017-2019
Kings County Hospital Center
2019
Triple-negative breast cancer (TNBC) is characterized by elevated locoregional recurrence risk despite aggressive local therapies. New tumor-specific radiosensitizers are needed. We hypothesized that the ATR inhibitor, VX-970 (now known as M6620), would preferentially radiosensitize TNBC. Noncancerous epithelial and TNBC cell lines were investigated in clonogenic survival, cycle, DNA damage signaling repair assays. In addition, patient-derived xenograft (PDX) models generated prospectively...
INTRODUCTION: Mycophenolate mofetil (MMF) is an immunosuppressive drug widely used in organ and bone marrow transplant recipients as well autoimmune disorders like systemic lupus erythematosus(SLE). Gastrointestinal side effects occur about 45% of patients using MMF, manifesting nausea, vomiting, diarrhea, abdominal pain. Here we illustrate a case diffuse colitis induced by MMF diagnosed colonoscopy histology. CASE DESCRIPTION/METHODS: 55-year old woman presented to hospital due asymptomatic...
Sherchan, Sunil; Kahila, Mohamed; Durrani, Jamrose K.; Puri, Isha; Mohamed, Ibrahim A.; Melaku, Yohannes; Yap, Ernie; Leonardo, Robert F.; Saggi, Subodh J.; Salifu, Moro O.; Nicastri, Anthony D. Author Information
<div>Abstract<p>Triple-negative breast cancer (TNBC) is characterized by elevated locoregional recurrence risk despite aggressive local therapies. New tumor-specific radiosensitizers are needed. We hypothesized that the ATR inhibitor, VX-970 (now known as M6620), would preferentially radiosensitize TNBC. Noncancerous epithelial and TNBC cell lines were investigated in clonogenic survival, cycle, DNA damage signaling repair assays. In addition, patient-derived xenograft (PDX)...
<p>Supplementary Figure S1 demonstrates that VX-970 exhibits minimal single agent activity at the dose which radiosensitized TNBC cells.</p>
<p>Supplementary Figure S2 demonstrates individual tumor volume data of MCTNBC1, MCTNBC2, MCTNBC3, and MCTNBC4 for the experiment shown in figure 5.</p>